Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 09:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced...
November 03, 2025 08:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue

OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the European Patent Office has officially granted AIM’s European...
October 20, 2025 09:15 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced it will participate at the 2025 Maxim Growth Summit, taking place...
September 25, 2025 14:23 ET | Source: AIM ImmunoTech Inc.

AIMイムノテック (AIM ImmunoTech)、アンプリジェン (Ampligen®)(リンタトリモド) とチェックポイント阻害剤を併用する新規がん治療に関する特許を日本で2039年まで取得

この特許は、ライセンス供与、共同研究、長期的な収益成長の機会を提供し、国際市場での保護拡大を目指すAIMの戦略を支えるものである日本は世界第3位の医薬品市場であり、がん領域は最も成長が速い治療分野であるフロリダ州オカラ発, Sept. 26, 2025 (GLOBE NEWSWIRE) -- AIMイムノテック (AIM ImmunoTech Inc.) (NYSE...
September 25, 2025 08:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is the third-largest pharmaceutical...
September 22, 2025 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth

OCALA, Fla., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Journal for ImmunoTherapy of Cancer (JITC) has published a...
September 04, 2025 11:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI...
August 21, 2025 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

OCALA, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
August 15, 2025 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the...
August 14, 2025 08:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

OCALA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Webull Financial Corporate Connect...